Cardiovascular disease (CVD) remains the leading cause of mortality globally, necessitating an effective risk assessment strategy. A comprehensive approach is crucial due to the multifactorial nature of CVD, encompassing genetic, environmental and lifestyle factors.
Genetic predisposition plays a significant role in CVD risk. With advancements in genetic testing, identifying high-risk individuals has become more accurate. However, the complexity of genetic interactions and the influence of epigenetic factors necessitate a nuanced approach to interpreting these results.
Environmental determinants such as air pollution and secondhand smoke significantly contribute to CVD risk. Exposure to these factors can lead to oxidative stress and inflammation, promoting atherosclerosis. Therefore, a comprehensive risk assessment should consider the patient's environmental exposures.
Diet, physical inactivity, and tobacco use are major modifiable risk factors for CVD. A comprehensive risk assessment should include a thorough lifestyle evaluation, with emphasis on identifying and addressing these modifiable risk factors.
Recent research has highlighted the role of biomarkers in predicting CVD risk. High-sensitivity C-reactive protein (hs-CRP), Lipoprotein(a), and homocysteine are among the emerging biomarkers. Incorporating these tests into routine risk assessment can provide additional predictive value.
Imaging techniques such as coronary calcium scoring and carotid intima-media thickness measurement have shown promise in improving risk prediction. These non-invasive methods provide direct evidence of subclinical atherosclerosis, thereby enhancing risk stratification.
A comprehensive approach to CVD risk assessment necessitates the integration of genetic, environmental, lifestyle factors, along with novel biomarkers and imaging techniques. Such an approach allows for a more accurate prediction of CVD risk, facilitating early intervention and improved patient outcomes.
1.
High Response Rate in Heavily Treated Multiple Myeloma With Novel Drug Combination
2.
Measurable Residual Disease Predicts Real-World AML Relapse
3.
Chemotherapy can be a challenging treatment?here's how to deal with some of the side-effects
4.
Black women are more likely to die of breast cancer. Close the gap by looking into mammogram studies.
5.
Admissions, medical schools, costs, and eligibility requirements information for FNB Head and Neck Oncology.
1.
Modern Developments in Oncology for Specialists
2.
Case-Based Learning: Reasoning Through New Functional Changes During Long-Term Cancer Survivorship
3.
The Latest Advances in Glioblastoma Treatment and Prevention
4.
How is Digital Innovation Revolutionizing Gynecologic Oncology Treatment and Patient Engagement?
5.
Treating Oral Fibromas: Options and Guidelines for a Healthier Mouth
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
2.
Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
4.
Understanding Iron Deficiency and Its Common Symptoms
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation